Drug Database
Back to search

Belgium· BE-AMP-SAM319742-00

Confidex 500 IU

A coagulation factor ix, ii, vii and x in combination product containing protein c, registered in Belgium by CSL Behring. The same ATC class is registered in 11 of our 19 countries.

ATC B02BD01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedConfidex 500 IUATCB02BD01REGISTER NO.BE-AMP-SAM319742-00PACKS LISTED2CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about protein cAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Coagulation factor ix, ii, vii and x in combination is registered in 11 of 19 countries.

Countries holding a registration under ATC B02BD01 (coagulation factor ix, ii, vii and x in combination), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 7 of them publish a price we can compare per daily dose
Search coagulation factor ix, ii, vii and x in combination products by name

Coagulation factor ix, ii, vii and x in combination · ATC B02BD01

11 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Protein C
Manufacturer
CSL Behring
Country
Belgium (BE)
ATC code
B02BD01
ATC class
Coagulation factor IX, II, VII and X in combination
Defined daily dose
1.6 TSD, E
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 2

  • be_apb
    2546398
  • be_apb
    0797720

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for coagulation factor ix, ii, vii and x in combination.

Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check coagulation factor ix, ii, vii and x in combination against other medicinesHow interaction checks work

Coagulation factor ix, ii, vii and x in combination · interactions on record

3 records

  • 2 severe
  • 1 moderate

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • PegvaliaseA16AB19moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Coagulation factor ix, ii, vii and x in combination in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All coagulation factor ix, ii, vii and x in combination products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • France · Protexel
  • Iceland · Ceprotin
  • Liechtenstein · Ceprotin
  • Norway · Ceprotin

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ce63c01b-76d7-4f46-92b3-f112051f2a26
GET /v1/drugs/ce63c01b-76d7-4f46-92b3-f112051f2a26?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Powder and solvent for solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "Confidex 500 IU",
  "name_fr": "Confidex 500 IU",
  "name_nl": "Confidex 500 IU",
  "amp_code": "SAM319742-00",
  "strengths": [
    "300.0000",
    "240.0000",
    "440.0000",
    "400.0000",
    "200.0000",
    "400.0000",
    "8.0000",
    "60.0000"
  ],
  "pack_count": 1,
  "substances": [
    "Protein C",
    "Protein S",
    "Human coagulation factor X",
    "Human Coagulation Factor II",
    "Human Coagulation Factor VII",
    "Human Coagulation Factor IX",
    "Heparin",
    "Sodium Chloride",
    "Sodium Hydroxide"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Coagulation Factor IX, II, VII and X in Combination",
  "authorisation_numbers": [
    "BE319742"
  ]
}
API referenceMCP serverPlans

See everything about coagulation factor ix, ii, vii and x in combination.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console